#6 - AbbVie (NYSE:ABBV)
It was a little understandable that investors cooled on AbbVie (NYSE:ABBV) in 2020. Investor dollars in the biotech sector were flooding into companies racing for a Covid-19 vaccine or therapeutic. Some investors were also a little unsure about revenue as the company’s flagship drug, Humira, had lost its European patent protections.
But Humira is still protected in the United States through 2022. In the meantime, the company has a strong pipeline with drugs like Skyrizi and Rinvoq. Plus the company acquired Allergan in 2020 which only adds to the company’s potential growth.
And AbbVie is a great example of a company that delivers both a large dividend and a great yield. The current quarterly dividend is $1.30 per share and has increased 84% in the last three years. And the company’s current dividend yield is 4.70%.
ABBV shares are only up 5% since the start of the year which is presenting investors with a terrific opportunity to enter or expand their position in this forever stock.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Read More - Current Price
- $178.65
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 19 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $205.50 (15.0% Upside)
